Soft Tissue Sarcoma With Lung Metastasis Market and Epidemiology Analysis
The Soft Tissue Sarcoma (STS) with lung metastases market is gaining increased attention from researchers, clinicians, and pharmaceutical developers as the unmet medical need in this indication remains critically high. Metastasis is not uncommon in STS; approximately 40% to 50% of individuals diagnosed with STS will eventually develop metastatic disease. Among all possible metastatic sites, the lungs are by far the most common destination, accounting for nearly 80% of first metastatic occurrences.
Patients presenting with STS of the lower extremity, higher tumor grade, and histological subtypes including leiomyosarcoma, spindle cell, or synovial cell sarcoma are more likely to develop lung metastases. Pulmonary metastasectomy is widely accepted as a standard treatment approach for lung metastases originating from STS.
While metastatic STS carries a poorer prognosis, aggressive interventions such as metastasectomy and stereotactic body radiation therapy (SBRT) can meaningfully improve survival outcomes, which currently range from 26% to 30%. Patients with lung metastases demonstrate worse survival compared to those without metastases; however, those with isolated lung metastases tend to fare better than patients presenting with any combination of lung, bone, brain, and/or liver metastases.
There are currently no therapies specifically approved for STS with lung metastases. While various systemic therapies are employed to manage metastatic STS broadly, none are uniquely indicated for lung metastases specifically. Annamycin (Moleculin Biotech) and Volrustomig (MEDI5752) combined with SBRT (Institut Claudius Regaud/AstraZeneca) represent the only known drugs in active clinical development targeting this specific patient population.
Recent Developments:
- In June 2025, Moleculin Biotech reported promising efficacy results for Annamycin from its Phase Ib/II clinical trial in patients with STS-LM, demonstrating encouraging anti-tumor activity in a heavily pretreated and difficult-to-treat population
- The data supports Annamycin’s potential role as a novel systemic option for pulmonary metastatic sarcoma and reinforces continued clinical development in this setting
- In September 2023, Immunophotonics reported that the first patient was dosed in its multinational clinical trial in France, marking a key milestone in the clinical development of its investigational immunotherapy program
- In December 2020, Moleculin Biotech reported that the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Annamycin for the treatment of soft tissue sarcomas
Soft Tissue Sarcoma With Lung Metastasis Understanding
Soft Tissue Sarcoma With Lung Metastasis Overview and Diagnosis
Soft Tissue Sarcoma is a diverse group of rare malignant tumors originating in mesodermal tissues – including fat, muscle, blood vessels, deep skin layers, tendons, and ligaments – that support and connect various parts of the body. While these tumors can occur anywhere, they most commonly begin in the arms or legs, though they can also develop in the trunk, head and neck, internal organs, or the retroperitoneal space located behind the abdominal cavity.
One of the foremost challenges in STS is its tendency to spread beyond the original tumor site. Approximately 40% to 50% of individuals with STS will eventually develop metastatic disease, and among all possible sites, the lungs remain the most frequent destination – accounting for nearly 80% of first metastatic occurrences.
When STS spreads to the lungs, it typically signals a more advanced disease stage, necessitating a fundamental shift in treatment goals – from curative intent toward controlling disease progression, alleviating symptoms, and extending survival. STS with lung metastasis is diagnosed through a combination of imaging scans, biopsies, and in select cases blood tests. Imaging modalities such as chest X-rays, CT scans, and MRIs can reveal the presence of pulmonary nodules or masses, while biopsies – where tissue samples are examined under a microscope – confirm the diagnosis and identify the specific sarcoma subtype.
The Soft Tissue Sarcoma (STS) with lung metastases market research landscape encompasses a thorough overview of the pathophysiology and diagnostic approaches for STS-LM, along with a real-world patient journey – beginning from the onset of first symptoms through the time to diagnosis and the complete treatment pathway.
Soft Tissue Sarcoma With Lung Metastasis Treatment
Pulmonary metastases represent a hallmark of advanced disease and consistently pose one of the most complex management challenges in oncology. The cornerstone of treatment remains surgical resection of all metastatic nodules, offering a potentially curative option and a demonstrated survival advantage. In the setting of metastatic sarcoma, lung involvement is frequent, and disease recurrence follows a markedly higher pattern than observed in most other solid tumor types. Multiple or even extended surgical operations are therefore often necessary.
Alongside surgical approaches, medical therapy has been employed with variable results across different patient populations. Currently, single-agent chemotherapy or combination regimens are reserved for patients with chemosensitive histology or those being considered for multimodality therapy. The role of immunotherapy, despite generating some promising early-phase signals, remains under active investigation and has not yet established a defined role in standard practice.
Radiotherapy has experienced a significant resurgence in recent years, driven largely by the broader adoption of SBRT, which has meaningfully challenged the traditional assumption of sarcoma radioresistance. These evolving treatment modalities are reshaping the therapeutic landscape for STS-LM, and the Soft Tissue Sarcoma (STS) with lung metastases market insight continues to reflect growing interest in combination and multimodal strategies.
Soft Tissue Sarcoma With Lung Metastasis Epidemiology
The epidemiology chapter in the STS with lung metastasis report is developed using a patient-based model and provides both historical and forecasted epidemiology data. The analysis is segmented by total incident cases of STS, total incident cases of STS-LM, and gender-specific incident cases of STS-LM across the 7MM – covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan – spanning the period from 2022 to 2036.
Key findings from the Soft Tissue Sarcoma With Lung Metastasis Epidemiological Analysis and Forecast:
- STS represents a meaningful oncologic burden, with approximately 14,000 new cases diagnosed annually in the United States; notably, up to 50% of these patients eventually develop lung metastases, highlighting the substantial progression risk and clinical impact of STS-LM
- In Germany, STS has an incidence of approximately 6.05 cases per 100,000 population, reflecting a notable disease burden and the potential for progression to advanced and metastatic stages such as STS-LM
- In Japan, STS has an incidence of approximately 3.22 cases per 100,000 population per year, reflecting a measurable but clinically significant disease burden with a meaningful potential for progression to STS-LM
Soft Tissue Sarcoma With Lung Metastasis Drug Analysis
The drug chapter segment of the STS with lung metastasis therapeutics market report encompasses a detailed analysis of both marketed drugs and late-stage (Phase III and Phase II) pipeline candidates. It also provides an in-depth examination of pivotal clinical trial details, recent and anticipated market approvals, patent landscapes, latest news, and recent deals and collaborations.
Soft Tissue Sarcoma With Lung Metastasis Emerging Drugs
Annamycin – Moleculin Biotech
Annamycin is an investigational next-generation anthracycline developed by Moleculin Biotech, specifically designed to overcome multidrug resistance. It incorporates a lipid-based delivery mechanism to enhance tumor uptake while reducing cardiotoxicity, with its development focused on aggressive and treatment-refractory cancers – including select sarcoma subtypes and hematologic malignancies. Currently in Phase I/II clinical development, Annamycin received Orphan Drug Designation from the FDA in December 2020 for the treatment of soft tissue sarcomas. The June 2025 Phase Ib/II data readout demonstrated meaningful anti-tumor activity in the STS-LM population, marking a critical step toward addressing a long-standing gap in this indication.
IP-001 – Immunophotonics
IP-001 is an investigational intratumoral immunotherapy developed by Immunophotonics for soft tissue sarcoma. It employs a photothermal mechanism to induce localized tumor cell death and stimulate systemic anti-tumor immune responses, with its development focused on advanced and refractory sarcoma settings. Currently in Phase I/II clinical development for both non-small cell lung cancer and STS, with Phase I enrollment for STS already completed. The first patient was dosed in Immunophotonics’ multinational clinical trial in France in September 2023, marking a key clinical milestone in the development of this investigational immunotherapy.
Leading Players in the Soft Tissue Sarcoma With Lung Metastasis Market
The leading players in the Soft Tissue Sarcoma with Lung Metastasis market include Moleculin Biotech Inc. and others who are advancing novel therapeutic strategies to address this high unmet-need indication. The competitive landscape, while still nascent, is expected to evolve substantially as clinical programs progress through development phases.
Conclusion
The STS-LM therapeutic landscape remains one of the most underserved areas in oncology, defined by a near-complete absence of specifically approved therapies and a patient population that carries a disproportionately poor prognosis. The Soft Tissue Sarcoma (STS) with lung metastases market trends clearly reflect an acceleration in drug development activity, driven by emerging clinical-stage assets like Annamycin and growing recognition of the unmet need within this niche but clinically significant population. With the 7MM epidemiology forecasts projecting sustained incidence burdens through 2036 and increasing investment in multimodal treatment strategies – including SBRT combinations and novel immunotherapy approaches – the market is positioned for meaningful evolution over the coming decade. Stakeholders across pharma, biotech, and the clinical research community are increasingly directing attention and capital toward STS-LM, a shift that is likely to accelerate as promising Phase II data mature into pivotal-stage evidence.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
